485 related articles for article (PubMed ID: 10467366)
41. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells.
Rubsam LZ; Boucher PD; Murphy PJ; KuKuruga M; Shewach DS
Cancer Res; 1999 Feb; 59(3):669-75. PubMed ID: 9973216
[TBL] [Abstract][Full Text] [Related]
42. Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma.
Sakai Y; Kaneko S; Nakamoto Y; Kagaya T; Mukaida N; Kobayashi K
Cancer Gene Ther; 2001 Oct; 8(10):695-704. PubMed ID: 11687892
[TBL] [Abstract][Full Text] [Related]
43. Gene therapy against an experimental glioma using adeno-associated virus vectors.
Okada H; Miyamura K; Itoh T; Hagiwara M; Wakabayashi T; Mizuno M; Colosi P; Kurtzman G; Yoshida J
Gene Ther; 1996 Nov; 3(11):957-64. PubMed ID: 8940635
[TBL] [Abstract][Full Text] [Related]
44. (E)-5-(2-bromovinyl)-2'-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase--expressing cells.
Hamel W; Zirkel D; Mehdorn HM; Westphal M; Israel MA
Cancer Gene Ther; 2001 May; 8(5):388-96. PubMed ID: 11477459
[TBL] [Abstract][Full Text] [Related]
45. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
46. Characterization of HIV-1 TAT peptide as an enhancer of HSV-TK/GCV cancer gene therapy.
Rautsi O; Lehmusvaara S; Ketola A; Määttä AM; Wahlfors J; Pellinen R
Cancer Gene Ther; 2008 May; 15(5):303-14. PubMed ID: 18309353
[TBL] [Abstract][Full Text] [Related]
47. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells.
Takamiya Y; Short MP; Ezzeddine ZD; Moolten FL; Breakefield XO; Martuza RL
J Neurosci Res; 1992 Nov; 33(3):493-503. PubMed ID: 1335091
[TBL] [Abstract][Full Text] [Related]
48. Suicide gene therapy of ovarian cancer: an experimental study in rats using retroviral-mediated transfer of herpes simplex virus thymidine kinase gene.
Nagy HJ; Panis Y; Fabre M; Klatzmann D; Houssin D; Soubrane O
Anticancer Res; 2000; 20(6B):4633-8. PubMed ID: 11205314
[TBL] [Abstract][Full Text] [Related]
49. Herpes simplex virus thymidine kinase gene transduction enhances tumor growth rate and cyclooxygenase-2 expression in murine colon cancer cells.
Konson A; Ben-Kasus T; Mahajna JA; Danon A; Rimon G; Agbaria R
Cancer Gene Ther; 2004 Dec; 11(12):830-40. PubMed ID: 15359292
[TBL] [Abstract][Full Text] [Related]
50. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.
Määttä AM; Tenhunen A; Pasanen T; Meriläinen O; Pellinen R; Mäkinen K; Alhava E; Wahlfors J
Int J Oncol; 2004 Apr; 24(4):943-9. PubMed ID: 15010834
[TBL] [Abstract][Full Text] [Related]
51. Contribution of a combination of ponicidin and acyclovir/ganciclovir to the antitumor efficacy of the herpes simplex virus thymidine kinase gene therapy system.
Hayashi K; Hayashi T; Sun HD; Takeda Y
Hum Gene Ther; 2002 Feb; 13(3):415-23. PubMed ID: 11860708
[TBL] [Abstract][Full Text] [Related]
52. A cell type-specific and gap junction-independent mechanism for the herpes simplex virus-1 thymidine kinase gene/ganciclovir-mediated bystander effect.
Princen F; Robe P; Lechanteur C; Mesnil M; Rigo JM; Gielen J; Merville MP; Bours V
Clin Cancer Res; 1999 Nov; 5(11):3639-44. PubMed ID: 10589781
[TBL] [Abstract][Full Text] [Related]
53. [Tegument viral protein 22 enhanced cell-killing effect of the herpes simplex virus thymidine kinase/ganciclovir system on ovarian cancer in vivo].
Kong BH; Wang WX; Liu CS; Ma DX; Qu X
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):195-8. PubMed ID: 12885362
[TBL] [Abstract][Full Text] [Related]
54. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.
Wildner O; Morris JC
J Gene Med; 2000; 2(5):353-60. PubMed ID: 11045429
[TBL] [Abstract][Full Text] [Related]
55. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.
Aghi M; Chou TC; Suling K; Breakefield XO; Chiocca EA
Cancer Res; 1999 Aug; 59(16):3861-5. PubMed ID: 10463570
[TBL] [Abstract][Full Text] [Related]
56. Treatment of rat experimental brain tumors by herpes simplex virus thymidine kinase gene-transduced allogeneic tumor cells and ganciclovir.
Namba H; Tagawa M; Miyagawa T; Iwadate Y; Sakiyama S
Cancer Gene Ther; 2000 Jun; 7(6):947-53. PubMed ID: 10880027
[TBL] [Abstract][Full Text] [Related]
57. Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy.
Miura F; Moriuchi S; Maeda M; Sano A; Maruno M; Tsanaclis AM; Marino R; Glorioso JC; Yoshimine T
Gene Ther; 2002 Dec; 9(24):1653-8. PubMed ID: 12457278
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of prodrugs ability to induce effective ablation of cells transduced with viral thymidine kinase gene.
Kuriyama S; Nakatani T; Masui K; Sakamoto T; Tominaga K; Yoshikawa M; Fukui H; Ikenaka K; Tsujii T
Anticancer Res; 1996; 16(5A):2623-8. PubMed ID: 8917361
[TBL] [Abstract][Full Text] [Related]
59. Resistance developing after long-term ganciclovir prodrug treatment in a preclinical model of NSCLC.
Kurdow R; Schniewind B; Boehle AS; Haye S; Boenicke L; Dohrmann P; Kalthoff H
Anticancer Res; 2004; 24(2B):827-31. PubMed ID: 15161034
[TBL] [Abstract][Full Text] [Related]
60. Suicide gene therapy for human uterine adenocarcinoma cells using herpes simplex virus thymidine kinase.
Kunishige I; Samejima Y; Shiki Y; Moriyama A; Meruelo D; Saji F; Murata Y
Gynecol Oncol; 1999 Jan; 72(1):16-25. PubMed ID: 9889024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]